| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
D. Boral Capital analyst Jason Kolbert maintains CervoMed (NASDAQ:CRVO) with a Buy and maintains $31 price target.
CervoMed (NASDAQ:CRVO) reported quarterly losses of $(0.84) per share which missed the analyst consensus estimate of $(0.49) by...
HC Wainwright & Co. analyst Raghuram Selvaraju upgrades CervoMed (NASDAQ:CRVO) from Neutral to Buy and raises the price ...
D. Boral Capital analyst Jason Kolbert maintains CervoMed (NASDAQ:CRVO) with a Buy and maintains $31 price target.
CervoMed's Phase 2b trial shows neflamapimod reduces dementia progression and plasma GFAP, with significant cognitive impro...